Exenatide News
Exenatide currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Exenatide with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Byetta is indicated for treatment of type-2 diabetes mellitus in combination with: metformin; sulphonylureas; thiazolidinediones; metformin and a sulphonylurea; metformin and a thiazolidinedione; ...
- Evidence level: L5
- Predicted indications (20):
- primary hereditary glaucoma (96.2%)
- open-angle glaucoma (95.4%)
- hypotrichosis simplex of the scalp (92.8%)
- congenital hypotrichosis milia (92.4%)
- headache disorder (91.8%)
- trigeminal autonomic cephalalgia (90.7%)
- diffuse alopecia areata (90.7%)
- alopecia (90.2%)
- obsolete rare pulmonary disease (89.5%)
- common cold (86.8%)
- glaucoma 1, open angle (86.7%)
- filariasis (86.7%)
- hyperplasia (86.5%)
- selective pituitary resistance to thyroid hormone (85.2%)
- gout (85.1%)
- thyroid gland disease (85.1%)
- toxic diffuse goiter (83.6%)
- digitalis poisoning (83.5%)
- renin-angiotensin-aldosterone system-blocker-induced angioedema (83.3%)
- thyroid crisis (disease) (82.4%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.